Showing 6371-6380 of 7113 results for "".
- Novan Forms New Advisory Council Focused on Nitric Oxide Technologies in Dermatologyhttps://practicaldermatology.com/news/novan-forms-new-advisory-council-focused-on-nitric-oxide-technologies-in-dermatology/2458228/Novan, Inc. has formed an Advisory Council comprised of key opinion leaders with broad expertise in dermatology. These leading physicians will provide medical advice and drug-development insight to the Company’s senior leadership team and board of directors. The Advisory Council will
- Positive Results Announced from SebuDerm Gel Study in Treatment of Seborrheic Dermatitishttps://practicaldermatology.com/news/positive-results-announced-from-sebuderm-gel-study-in-treatment-of-seborrheic-dermatitis/2458237/The results of a clinical study evaluating the impact of Sonoma Pharmaceuticals, Inc.'s SebuDerm (topical hypochlorous acid) gel in the treatment of mild to moderate facial and scalp seborrheic dermatitis were presented at the 13th Annual Maui Dermatology Conference in Maui, HI.
- Heliocare Spotlights Improved Formulation: Vegan, Gluten-free, and Dye-freehttps://practicaldermatology.com/news/heliocare-spotlights-improved-formulation-vegan-gluten-free-and-dye-free/2458243/Heliocare Daily Use Antioxidant Formula, a clinically proven, natural dietary supplement with antioxidant effects on the skin, has been updated to be vegan, gluten-free, and free of artificial dyes. The once-daily capsules from Ferndale Healthcare, have been recommended by dermatologists fo
- RepliCel's Baldness Cure Performs Well In First In-Human Trialhttps://practicaldermatology.com/news/replicels-baldness-cure-performs-well-in-first-in-human-trial/2458246/The first in-human study of RepliCel Life Sciences Inc’s investigational baldness cure, RCH-01, confirms the therapy’s safety and demonstrates strong efficacy signals, the company reports. The autologous cell therapy involves culturing a person’s own dermal sheath cup ce
- Serlopitant May Stop the Itch of Prurigo Nodularishttps://practicaldermatology.com/news/serlopitant-may-stop-the-itch-of-prurigo-nodularis/2458252/Menlo Therapeutics Inc.’s Serlopitant performed well in phase 2 trial (TCP-102) evaluating it as a treatment of pruritus associated with prurigo nodularis, successfully meeting its primary efficacy endpoint and key sec
- New Biomarker May Help Guide Metastatic Melanoma Treatment Decisionshttps://practicaldermatology.com/news/new-biomarker-may-guide-metastatic-melanoma-treatment-decisions/2458253/Measuring levels of Bim—a protein made by cancer-fighting T cells—via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error ass
- Pierre Fabre and Hill Dermaceuticals Partner in Commercial Partnership for TOLAK for AKshttps://practicaldermatology.com/news/pierre-fabre-and-hill-dermaceuticals-partner-in-commercial-partnership-for-tolak-for-aks/2458258/Pierre Fabre Dermo-Cosmetique and Hill Dermaceuticals, Inc. have entered into a strategic commercial partnership for TOLAK, a patented prescription dermatologic drug, indicated for the topical treatment of actinic keratosis lesions of the face, ears, and/or scalp. Under the terms of the a
- Cutanea Unveils Aktipak Gel, 3%/5%, Convenient Acne Treatment for "On-the-Go" Patientshttps://practicaldermatology.com/news/cutanea-unveils-aktipak-gel-35-convenient-acne-treatment-for-on-the-go-patients/2458260/Cutanea Life Sciences, Inc. (CLS) introduced Aktipak (erythromycin and benzoyl peroxide) Gel, 3%/5%, a combination therapy indicated for the topical treatment of acne vulgaris. The product is available through dermatologists' offices. Aktipak is a portable, freshly mixed, p
- Galderma and Colorescience Launch Collaborationhttps://practicaldermatology.com/news/galderma-and-colorescience-launch-collaboration/2458265/Galderma will collaborate with Colorescience to expand skincare solutions to individuals who seek innovative daily skincare products that can be used in conjunction with traditional facial injectable aesthetic treatments, the companies have announced. Galderma and Color
- Galderma Moves to Differentiate Their Two New HA Fillers From The Frayhttps://practicaldermatology.com/news/galderma-moves-to-differentiate-their-two-new-ha-fillers-from-the-fray/2458262/With a growing number of hyaluronic acid (HA) fillers available and even more in the pike, Galderma is highlighting how their two newest fillers --Restylane Refyne and Restylane Defyne --stand out from the crowd. In a word: flexibility. Th